Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications

Steroids

Volumn 78, Issue 12-13, 2013, Pages 1273-1280

  Kangas, Lauri ^a   Unkila, Mikko ^a  

^a Hormos Nutraceutical Oy Ltd   (Finland)

Author keywords

Dyspareunia; Ospemifene; Selective estrogen receptor modulator; Vulvar and vaginal atrophy

Indexed keywords

ADVERSE DRUG REACTION; ALKALINE PHOSPHATASE; BROXURIDINE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; DIMETHYLBENZ[A]ANTHRACENE; DRUG DERIVATIVE; DRUG THERAPY; ERBIUM; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; LUTEINIZING HORMONE; OSPEMIFENE; OSTEOCALCIN; PHARMACOLOGY; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADVERSE EVENT; AE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL; ANTIBODY SPECIFICITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BMD; BONE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; BREAST CELL; BREAST TENDERNESS; CELL PROLIFERATION; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPAREUNIA; ED(50); ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM CELL; ENDOMETRIUM HYPERPLASIA; EPITHELIUM; ESTROGEN THERAPY; FEMALE; HALF-MAXIMAL EFFECTIVE DOSE; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; MAMMARY GLAND; MAMMARY INTRAEPITHELIAL NEOPLASIA OUTGROWTH; MATURATION; MENOPAUSE; MI; MIN-O; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMIZED; OVX; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREVENTION; REVIEW; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; URINARY TRACT INFECTION; UTERUS WEIGHT; VAGINA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA EPITHELIUM; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; VTE; VULVA DISEASE; VULVAR AND VAGINAL ATROPHY; VVA;

ADVERSE EVENT; AE; BMD; BONE MINERAL DENSITY; BRDU; BROMODEOXYURIDINE; DIMETHYLBENZANTHRACENE; DMBA; DYSPAREUNIA; ED(50); ER; ESTROGEN RECEPTOR; HALF-MAXIMAL EFFECTIVE DOSE; MAMMARY INTRAEPITHELIAL NEOPLASIA OUTGROWTH; MATURATION INDEX; MI; MIN-O; OSPEMIFENE; OVARIECTOMIZED; OVX; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERM; VENOUS THROMBOEMBOLISM; VTE; VULVAR AND VAGINAL ATROPHY; VVA;

ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMALS; BONE AND BONES; BONE RESORPTION; DRUG EFFECTS; EPITHELIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; ORGAN SPECIFICITY; PATHOLOGY; PHARMACOLOGY; PREVENTION AND CONTROL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; THERAPEUTIC USE; VAGINA;

ANIMALIA; RATTUS;

EID: 84885050196     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. E. Barrett-Connor, and G.A. Laughlin Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials Semin Reprod Med 27 2009 275 282
2. North American Menopause Society The 2012 hormone therapy position statement of The North American Menopause Society Menopause 19 2012 257 271
3. H.D. Nelson, M. Walker, B. Zakher, and J. Mitchell Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations Ann Intern Med 157 2012 104 113
4. X.Y. Dong, P. Guo, X. Sun, Q. Li, and J.T. Dong Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells J Biol Chem 286 2011 13879 13890
5. K. Wend, P. Wend, and S.A. Krum Tissue-specific effects of loss of estrogen during menopause and aging Front Endocrinol (Lausanne) 3 2012 19
6. L. Gennari Ospemifene hormos Curr Opin Investig Drugs 5 2004 448 455
7. S.L. Berga Profile of ospemifene in the breast Reprod Sci 20 2013 1130 1136
8. Osphena™ (ospemifene) Full prescribing information 2013 Shionogi Inc Florham Park, NJ
9. M.B. Mac Bride, D.J. Rhodes, and L.T. Shuster Vulvovaginal atrophy Mayo Clin Proc 85 2010 87 94
10. http://www.census.gov/2010census >; 2013 [accessed 13.02.13].
11. IMS Health Plan Claims [Apr 2008-Mar 2011].
12. M. Unkila, S. Kari, E. Yatkin, and R. Lammintausta Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause J Steroid Biochem Mol Biol 138 2013 107 115
13. S.K. Voipio, J. Komi, and L. Kangas Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women Maturitas 43 2002 207 214 (Pubitemid 35346550)
14. J. Komi, K.S. Lankinen, and P. Härkönen Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause 12 2005 202 209 (Pubitemid 40464289)
15. E.M. Rutanen, J. Heikkinen, and K. Halonen Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial Menopause 10 2003 433 439
16. G.A. Bachmann, J.O. Komi the Ospemifene Study Group Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause 17 2010 480 486
17. D.J. Portman, G.A. Bachmann, J.A. Simon the Ospemifene Study Group Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy Menopause 20 2013 623 630
18. S.R. Goldstein, G.A. Bachmann, and P.R. Koninckx Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy Climacteric 2013 [Epub ahead of print]
19. M.Y. Williams-Brown, S.M. Salih, and X. Xu The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk J Steroid Biochem Mol Biol 126 2011 78 86
20. J.A. Simon, V.H. Lin, C. Radovich, G.A. Bachmann The Ospemifene Study Group One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus Menopause 20 2013 418 427
21. W.Y. Chen, J.E. Manson, and S.E. Hankinson Unopposed estrogen therapy and the risk of invasive breast cancer Arch Intern Med 166 2006 1027 1032
22. Q. Qu, H. Zheng, and J. Dahllund Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology 141 2000 809 820 (Pubitemid 32250507)
23. T.L. Taras, G.T. Wurz, and M.W. DeGregorio In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer J Steroid Biochem Mol Biol 77 2001 271 279 (Pubitemid 32703625)
24. R.A. Burich, N.R. Mehta, and G.T. Wurz Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model Menopause 19 2012 96 103
25. G.T. Wurz, K.C. Read, and C. Marchisano-Karpman Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice J Steroid Biochem Mol Biol 97 2005 230 240 (Pubitemid 41607573)
26. R. Namba, L.J. Young, and J.E. Maglione Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ Breast Cancer Res 7 2005 R881 R889
27. M.C. Gutierrez, S. Detre, and S. Johnston Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase J Clin Oncol 23 2005 2469 2476 (Pubitemid 47050837)
28. Q. Qu, P.L. Härkönen, and H.K. Väänänen Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture J Cell Biochem 73 1999 500 507 (Pubitemid 29256939)
29. H. Michael, P.L. Härkönen, L. Kangas, H.K. Väänä nen, and T.A. Hentunen Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br J Pharmacol 151 2007 384 395 (Pubitemid 46842673)
30. J. Komi, J. Heikkinen, and E.M. Rutanen Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol 18 2004 152 158 (Pubitemid 38328094)
31. J. Komi, K.S. Lankinen, and M. DeGregorio Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab 24 2006 314 318 (Pubitemid 43992675)
32. O. Tan, K. Bradshaw, and B.R. Carr Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review Menopause 19 2012 109 117
33. J. Chow, J.H. Tobias, K.W. Colston, and T.J. Chambers Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation J Clin Invest 89 1992 74 78
34. R.T. Turner, J.J. Vandersteenhoven, and N.H. Bell The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats J Bone Miner Res 2 1987 115 122
35. B.L. Clarke, and S. Khosla Female reproductive system and bone Arch Biochem Biophys 503 2010 118 128
36. L.M. McNamara Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures J R Soc Interface 7 2010 353 372